The understanding of the role of human interleukin-3 (IL-3) in the pathogenesis of leukemias and the use of this information for design of new therapeutic strategies is the long term objective.
The specific aims are - 1. Definition of the biologic spectrum of activities of the newly discovered recombinant hIL-3 molecule. This will involve its effects on bone marrow, including potential for self-renewal and capacity for differentiation, as well as activation of mature cells. 2. The capacity of myeloid leukemic cells to respond to hIL-3 will be examined in a clonogenic assay. It is hypothesized that some leukemic cells will respond to IL-3 by differentiation (hence loss of clonogenic potential) while for others IL-3 will be essential for self-renewal. The response to IL-3 will help not only in providing a potentially useful basis for classification but also in indicating a rationale for use in therapy. 3. The number and affinity of receptors on normal bone marrow, mature or leukemic cells, will be estimated by radiolabelled ligand binding and the interaction of IL-3 with other colony- stimulating factors will also be addressed. 4. Chemical synthesis of the IL-3 molecule will be undertaken in order to explore regions of the molecule essential for function and then this information will be used to raise monoclonal antibodies against critical peptide segments. These peptides will be examined for biological function and subsequently for raising anti- idiotypes as possible probes for the IL-3 receptor. 5. The cDNA probe for hIL-3 will be used for defining the cellular source of IL-3. The study will be undertaken in bulk cell populations of normal and leukemic cells and also in in-situ hybridization to give precise anatomical localisation of the cells in question. These studies will give substantial information as to which cells have receptors and can respond to IL-3 and provide data on whether an abnormality of either production or responsiveness exists in myeloid leukemias and point to the type of leukemia in which therapeutic strategies may be most effective.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA045822-03
Application #
3189110
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1987-08-01
Project End
1990-07-31
Budget Start
1989-08-01
Budget End
1990-07-31
Support Year
3
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Institute of Medical and Vet Science
Department
Type
DUNS #
740198254
City
Adelaide
State
Country
Australia
Zip Code
5000
Korpelainen, E I; Gamble, J R; Smith, W B et al. (1995) Interferon-gamma upregulates interleukin-3 (IL-3) receptor expression in human endothelial cells and synergizes with IL-3 in stimulating major histocompatibility complex class II expression and cytokine production. Blood 86:176-82
Ryan, G R; Vadas, M A; Shannon, M F (1994) T-cell functional regions of the human IL-3 proximal promoter. Mol Reprod Dev 39:200-7
Hercus, T R; Bagley, C J; Cambareri, B et al. (1994) Specific human granulocyte-macrophage colony-stimulating factor antagonists. Proc Natl Acad Sci U S A 91:5838-42
Barry, S C; Bagley, C J; Phillips, J et al. (1994) Two contiguous residues in human interleukin-3, Asp21 and Glu22, selectively interact with the alpha- and beta-chains of its receptor and participate in function. J Biol Chem 269:8488-92
Hercus, T R; Cambareri, B; Dottore, M et al. (1994) Identification of residues in the first and fourth helices of human granulocyte-macrophage colony-stimulating factor involved in biologic activity and in binding to the alpha- and beta-chains of its receptor. Blood 83:3500-8
D'Andrea, R; Rayner, J; Moretti, P et al. (1994) A mutation of the common receptor subunit for interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor, and IL-5 that leads to ligand independence and tumorigenicity. Blood 83:2802-8
Vadas, M; Lopez, A; Gamble, J et al. (1994) Cytokines and allergy. J Allergy Clin Immunol 94:1289-93
Goodall, G J; Bagley, C J; Vadas, M A et al. (1993) A model for the interaction of the GM-CSF, IL-3 and IL-5 receptors with their ligands. Growth Factors 8:87-97
Kremer, E; Baker, E; D'Andrea, R J et al. (1993) A cytokine receptor gene cluster in the X-Y pseudoautosomal region? Blood 82:22-8
Lopez, A F; Shannon, M F; Barry, S et al. (1992) A human interleukin 3 analog with increased biological and binding activities. Proc Natl Acad Sci U S A 89:11842-6

Showing the most recent 10 out of 22 publications